An Analysis of the tnAcity Trial
Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.
Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer (TNBC).
Clinical Pearls:
- The tnAcity trial will measure the efficacy of combinations, such as gemcitabine and carboplatin, carboplatin and nab-paclitaxel (Abraxane), and gemcitabine and nab-paclitaxel
- During this phase II trial, which has about 80 patients enrolled, patients will be randomized to receive one of the three combinations
- Based on the results of the phase II trial, the two combinations that prove to be the most effective will be tested further
- The trial will also investigate biomarkers that will help physicians figure out how to optimally treat patients with TNBC
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
